|Daily Range||$26.56 - $26.73|
|52-Week Range||$20.36 - $26.73|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||114,530|
|Current FY EPS||$0.56|
News & Commentary
Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.
Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.
Motley Fool contributors offer up three potential acquisition targets for Pfizer.
What's the best way to lose weight? One company thinks it's simple: don't get hungry.
Seattle Genetics' shares get hammered following impressive clinical data from its rivals at the American Society of Hematology's annual meeting. Find out whether this dip represents a buying opportunity or a red flag.
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?
The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?
Takeda, Eli Lilly, Immunomedics, and Pharmacyclics could loom large in health care headlines this Tuesday morning.
Lower research and development expenses help lower Orexigen's quarterly loss.
A number of factors are holding back obesity therapies, but this one glimmer of light has the potential to change that perception.